What is “Drug Sequencing”?
An important question in treatment planning is the order in which drugs are given, known as “drug sequencing”. Read for expert opinions on this topic.
Non-Treatment Trials: Predicting Response to Treatment and Decision Support
This month, we are highlighting trials that study ways to predict how tumors respond to treatment and help guide treatment decisions. Click to learn more and find these types of trials on Metastatic Trial Search.
What are Clinical Practice Guidelines and How are They Developed?
Learn how experts develop and refine MBC treatment guidelines using evidence from MBC clinical trials.
ASCO Experts Update Guidance for Sacituzumab Govitecan (Trodelvy®) for HR+, HER2- MBC
Read for information on the FDA’s expanded approval of Trodelvy® and ASCO’s updated guidance on the use of this drug.
What is Stable Disease and How is it Monitored?
Read about stable disease and current research on monitoring MBC treatment response.
Biomarkers to Guide MBC Treatment Decisions: ESR1, PALB2, TROP2, HRD, ctDNA, and CTCs
In part 3 of a 3-part series, learn about biomarkers that require more research before being recommended to guide treatment decisions.
Biomarkers to Guide MBC Treatment Decisions: dMMR/MSI-H, TMB, and NTRK Fusion
In part 2 of a 3-part series, read about the new recommendations and the dMMR/MSI-H, TMB, and NTRK fusion biomarkers.
Biomarkers to Guide MBC Treatment Decisions: PIK3CA, BRCA1/BRCA2, and PD-L1/PD-1
In this part 1 of a 3-part series, read about new recommendations for using biomarkers to make MBC treatment decisions.
Lines of Therapy: New Drugs May Change MBC Treatment
Which therapy to use for the first, second or third line of treatment for metastatic breast cancer is now under rigorous research as more new therapies are available for treating MBC.
What Are Lines of Therapy and What You Need to Know
“Lines of therapy” describes the order in which therapies are given as MBC progresses. Learn how lines of therapy are chosen and about current MBC treatment guidelines.